Slow-transit constipation is a very common disease, whether associated with defecation disorders or not. Lifestyle and dietary measures and even laxatives, which represent the cornerstone of its management, rely on weak evidence. In addition, patients are frequently dissatisfied with commonly prescribed laxatives. New pharmacologic treatments of constipation have recently emerged, with a novel enterokinetic activity. Prucalopride (Resolor®) will be the first treatment of this kind available in France. Others are expected, and this new class of agents probably announces a change of era in the management of slow-transit constipation, which therapeutic strategy should be permanently modified.